Coronary artery disease (CAD) is the leading cause of morbidity and mortality in developed countries. In addition, many patients suffer from valvular and aortic disease. Although various tools are available to identify patients with cardiovascular (CV) disease at risk for major adverse cardiac events (MACE), the identification of these patients remains a clinical challenge. One promising avenue is the use of different serum biomarkers involved in atherothrombosis which could provide an easy and cost-effective step in risk stratification.
Study Type
OBSERVATIONAL
Enrollment
5,000
Maastricht University Medical Center
Maastricht, Limburg, Netherlands
RECRUITINGData registration of patients undergoing CCTA and given written informed consent.
Time frame: 15 years.
To detect these patients for cardiovascular disease and Long term CV outcome (MACE).
Time frame: 15 years.
The relationship of novel blood biomarkers with CCTA findings.
Time frame: 15 years.
The predictive value of these biomarkers to predict CAD in patients undergoing CCTA.
Time frame: 15 years.
The prognostic value of these biomarkers (in combination) to predict MACE.
Time frame: 15 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.